CD8A and neoplasm: Next, a combination of cytosolic delivery with Cell Squeeze® technology of HPV E6/E7 antigens in combination with IL-2 variants (IL-2v), anti-PD-1 and anti-fibroblast activation protein (FAP) which collectively favours natural killer cells and CD8+ T-cell responses, resulted in significantly improved survival compared to monotherapy groups in a murine Human Papilloma Virus tumour model (TC-1 cells) [212].